Isolated perfusion of pancreas with mitomycin C.
The current treatment of pancreatic cancer with resection and/or radiation is considered unsatisfactory because of a high incidence of failure and a moderate incidence of complications. A sizable number of these patients present with localized or regional disease. Regional high-dose chemotherapy, such as with isolated perfusion, may offer an alternative therapy with low treatment-related morbidity and mortality and better end results in this group of patients. In an effort to develop such a treatment modality, we evaluated the pharmacokinetics and toxicity of mitomycin C (MMC) during isolated perfusion of pancreas in a canine model. From this study, it appears that a dose of 0.25 mg MMC/kg body weight is most suitable for isolated perfusion of pancreas at 39 degrees C, maintaining flow rate and pressure within physiologic range. Isolated perfusion with a dose of 0.25 mg/kg body weight has very mild short- and long-term toxicities and markedly increases drug delivery to the pancreas, duodenum, and peripancreatic lymph nodes, making it the most suitable dose for possible clinical application.
Department of Surgery, Medical College of Ohio, Toledo 43699-0008.
M A
MA
Arredondo
B
B
Chaudhuri
R
R
Kar
K A
KA
Crist
N R
NR
Thomford
P K
PK
Chaudhuri
D000681:Amylases / Q000097:blood; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D010478:Chemotherapy, Cancer, Regional Perfusion; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D004386:Duodenum / Q000378:metabolism; D007958:Leukocyte Count; D008049:Lipase / Q000097:blood; D008198:Lymph Nodes / Q000378:metabolism; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D010179:Pancreas / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000188:drug therapy
D001786:Blood Glucose; D008937:Mitomycins; D016685:Mitomycin; D008049:Lipase; D000681:Amylases